I was just looking to get a little more feedback on your thoughts of PCOP's pipeline. I was a former PCOP shareholder and now own some LGND given the merger. PCOP had quite an extensive pipeline (http://www.pharmacopeia.com/wt/page/product_portfolio ) at the time of the merger with LGND along with numerous partnerships (Schering-Plough, BMS, GSK, Celgene, and Wyeth) so I'm not sure what you had against their pipeline.
PCOP's lead compound was a dual-acting angiotensin and endothelin receptor antagonist targeting hypertension. See: http://www.pharmacopeia.com/wt/page/PS433540. I'm curious if you or others have any opinions on this compound.
Market Data 
Markets 
AI
